Jonathan Brouillette, PhD, University of Montreal, Montreal, Quebec, Canada, outlines a study investigating whether neuroligin-1 (NLGN1) is altered in the hippocampus of Alzheimer’s disease (AD) patients as well as whether it modulates cognitive functions during Aβo-driven neurodegeneration. This interview was recorded during an online conference call with The Video Journal of Dementia (VJDementia).